跳至主要内容
临床试验/EUCTR2008-008353-35-FR
EUCTR2008-008353-35-FR进行中(未招募)1 期

EFFICACY STUDY OF A CICLOPIROXOLAMINE 1% FOAM (DC115 GM 02A) VERSUS CICLOPIROXOLAMINE 1.5% SHAMPOO (SEBIPROX®) IN THE TREATMENT OF MODERATE SEBORRHEIC DERMATITIS OF THE SCALP

PIERRE FABRE DERMATOLOGIE REPRESENTED BY INSTITUT DE RECHERCHE PIERRE FABRE0 个研究点目标入组 44 人开始时间: 2009年3月17日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients must meet all the following criteria to enter the study:
  • -Patients aged more than 18 years old,-Stable or exacerbating seborrheic dermatitis of the scalp as evidenced by a score of scaling and erythema between 2 to 4,
  • -Comparable intensity of seborrheic dermatitis on both sides of the half head,
  • -Patients who agree to stop application of any topical product (drugs and/or cosmetics) on the scalp and use only the delivered soft shampoo during the study period,
  • -Written Informed Consent Form obtained from the patient,
  • -Patient willing to attend the planned all visits at the investigational centre and to comply with all trial requirements,
  • -Patient registered with a social security,
  • -For woman of childbearing potential:
  • ?negative urine pregnancy test at inclusion,
  • ?use an efficient method of contraception (implants, injectables, oral contraceptives, intra-uterine devices, tubal ligature) for at least 2 months before the study, during and one month after the end of the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Patients who have one of the following criteria will not be allowed to enter the study:
  • * Related to the pathologies
  • -Severe seborrheic dermatitis requiring a treatment with corticosteroids,
  • -Psoriasis of any type and anywhere on the body,
  • -Asthma requiring regular treatment with corticosteroids (inhaled, oral or injectable),
  • -History and/or current disease of immunosuppression,
  • -Parkinson disease,
  • -History of a major medical/psychiatric illness or surgery which, in the judgement of the investigator, may interfere with study medication, metabolism and/or study implementation and/or study parameter assessment(s).
  • *Related to treatments
  • -Patients with a history of hypersensitivity to ciclopiroxolamine and/or to at least one ingredient of the products,
  • -Treatment with any other investigational product in the 4 weeks prior to the inclusion visit,
  • -Topical treatment of the scalp with other antifungal medication, retinoids, erythromycin, tetracycline or any of its derivates, trimethoprim/sulfamethoxazole, metronidazole, or corticosteroids within the 2 weeks prior the inclusion visit,
  • -Systemic use of retinoids, erythromycin, tetracycline or any of its derivates, trimethoprim/sulfamethoxazole, or metronidazole within the 4 weeks prior to the inclusion visit,
  • -Systemic use of corticosteroids within the 12 weeks prior to the inclusion visit,
  • * Related to the population
  • -Sensitive skin to topical or cosmetic products,
  • -History of drug or alcohol abuse,
  • -Female who is pregnant or breast feeding or not using contraception, or planning to become pregnant,
  • -Participation to an other clinical trial in the previous month or during the study,
  • -Patient who, is not able to understand the information (for linguistic or psychiatric reasons) and to give informed consent,
  • -Patient who, in the judgement of the investigator, is not likely to be compliant during the study,
  • -Patient who has forfeited his/her freedom by administrative or legal decision, or who is under guardianship.

研究者

发起方
PIERRE FABRE DERMATOLOGIE REPRESENTED BY INSTITUT DE RECHERCHE PIERRE FABRE

相似试验